CD4 and HIV-1 infection: In particular, the RV144 trial demonstrated that CD4+ T cell-mediated responses, but not CD8+ T cell-mediated responses, were predominantly effectively elicited in vaccinees, and the CD4+ T cell response correlates and contributes to protection efficacy against HIV-1 infection.